Lidocaine for Oxaliplatin-induced Neuropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03254394|
Recruitment Status : Recruiting
First Posted : August 18, 2017
Last Update Posted : January 15, 2019
Washington University School of Medicine
Information provided by (Responsible Party):
simon.haroutounian, Washington University School of Medicine
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Recruiting|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||June 1, 2021|
Publications of Results:
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014 Dec;155(12):2461-70. doi: 10.1016/j.pain.2014.09.020. Epub 2014 Sep 23. Review.
Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology. 2004 Jan 27;62(2):218-25.